NEW YORK (GenomeWeb News) – Ferrer inCode, the biotech subsidiary of Spanish firm Grupo Ferrer, has gained exclusive rights to sell two of Agendia’s cancer diagnostic services in certain European countries, the firms said today.
 
Ferrer will offer Agendia’s MammaPrint and CupPrint tests in Germany, France, Italy, and Portugal. Ferrer already sells the tests in Spain under an agreement signed last year.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.